William Blair Reaffirms “Outperform” Rating for Mersana Therapeutics (NASDAQ:MRSN)
William Blair reissued their outperform rating on shares of Mersana Therapeutics (NASDAQ:MRSN – Free Report) in a report released on Tuesday,RTT News reports. Other analysts also recently issued reports about the company. Wedbush restated an “outperform” rating and issued a $3.00 price objective on shares of Mersana Therapeutics in a report on Thursday, May 15th. […]
William Blair reissued their outperform rating on shares of Mersana Therapeutics (NASDAQ:MRSN – Free Report) in a report released on Tuesday,RTT News reports. Other analysts also recently issued reports about the company. Wedbush restated an “outperform” rating and issued a $3.00 price objective on shares of Mersana Therapeutics in a report on Thursday, May 15th. […]
